OpenEvidence bypasses hospital procurement cycles

Free access let OpenEvidence grow like a consumer app inside medicine, instead of waiting for a hospital to approve a budget line. A doctor can start using it alone, on day one, because it does not require the hospital to buy seats first, and early adoption spread before IT and procurement got involved. That is the opposite of UpToDate, where institutional contracts still drive most revenue and rollout.1 2 3 4 5

• OpenEvidence itself tied its early growth to being free and avoiding patient records, which helped it bypass roughly 18 month healthcare sales cycles and build bottom up usage among physicians before moving into enterprise integrations later.1 2
• This playbook only works because the product is useful to an individual doctor without a hospital deployment. Clinicians can ask case questions and get journal grounded answers immediately, much like Doximity grew through physician by physician adoption for tools that also did not depend on protected health information.1 6 7
• The contrast with UpToDate is structural. Wolters Kluwer says most UpToDate revenue comes from institutional customers, and by the end of 2025 it had migrated most large U.S. enterprise customers to UpToDate Enterprise, showing a top down sales motion built around health system contracts.3 4 5

The next step is turning physician level usage into system level control points inside the EHR. If OpenEvidence keeps converting free daily use into enterprise workflow integrations, it can move from being a fast reference tool to becoming part of how hospitals make care decisions, which raises both revenue per account and switching costs.2 8